Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil VSports app下载. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

Comparative Study
. 2015 Dec 22;13(1):ijerph13010012.
doi: 10.3390/ijerph13010012.

PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer?

Adeodat Ilboudo  1 , Jyoti Chouhan  2 , Brian K McNeil  3 , Joseph R Osborne  4 , Olorunseun O Ogunwobi  5   6
Affiliations
Comparative Study

PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer?

"VSports手机版" Adeodat Ilboudo et al. Int J Environ Res Public Health. .

Abstract

Prostate cancer (PCa) is the most commonly diagnosed cancer as well as the greatest source of cancer-related mortality in males of African ancestry (MoAA). Interestingly, this has been shown to be associated with single nucleotide polymorphisms around regions 2 and 3 of the 8q24 human chromosomal region. The non-protein coding gene locus Plasmacytoma Variant Translocation 1 (PVT1) is located at 8q24 and is overexpressed in PCa and, therefore, is also a candidate biomarker to explain the well-known disparity in this group. PVT1 has at least 12 exons that make separate transcripts which may have different functions, all of which are at present unknown in PCa. Our aim was to determine if any PVT1 transcripts play a role in aggressiveness and racial disparity in PCa VSports手机版. We used a panel of seven PCa cell lines including three derived from MoAA. Ribonucleic acid extraction, complementary deoxyribonucleic acid synthesis, and quantitative polymerase chain reaction (qPCR) were performed to evaluate expression of all 12 PVT1 exons. Each qPCR was performed in quadruplicates. At least four separate qPCR experiments were performed. Expression of PVT1 exons was inconsistent except for exon 9. There was no significant difference in exon 9 expression between cell lines derived from Caucasian males (CM), and an indolent cell line derived from MoAA. However, exon 9 expression in the aggressive MDA PCa 2b and E006AA-hT cell lines derived from MoAA was significantly higher than in other cell lines. Consequently, we observed differential expression of exon 9 of PVT1 in a manner that suggests that PVT1 exon 9 may be associated with aggressive PCa in MoAA. .

Keywords: PVT1 exon 9; biomarker; disparity; males of African ancestry; prostate cancer V体育安卓版. .

PubMed Disclaimer

Figures (V体育2025版)

Figure 1
Figure 1
PVT1 localization on chromosome 8q24. PVT1 is a 300 kb long non-protein coding gene locus found at the 8q24 human chromosomal region. The PVT1 gene locus comprises at least 12 annotated exons.
Figure 2
Figure 2
PVT1 exons 1a (A); 1b (B) and 1c (C) expression in non-tumorigenic and tumorigenic prostate epithelial cell lines. Four independent qPCR experiments were performed and every experiment was set up in quadruplicates. The data showed that there is no significant differential expression of the exons in the cell lines in comparing cell lines derived from CM with those derived from MoAA. The data are presented as mean + standard error of the mean (SEM).
Figure 3
Figure 3
PVT1 exons 2 (A); 3b (B); and 4a (C) expression in non-tumorigenic and tumorigenic prostate epithelial cell lines. Four (for exon 2 and exon 3b) or 3 (for exon 4a) independent qPCR experiments were performed and every experiment was set up in quadruplicates. The data showed that there is no significant differential expression of the exons in the cell lines in comparing cell lines derived from CM with those derived from MoAA. The data are presented as mean + standard error of the mean (SEM).
Figure 4
Figure 4
PVT1 exons 4b (A); 5 (B) and 6 (C) expression in non-tumorigenic and tumorigenic prostate epithelial cell lines. Four independent qPCR experiments were performed and every experiment was set up in quadruplicates. The data showed that there is no significant differential expression of the exons in the cell lines in comparing cell lines derived from CM with those derived from MoAA. The data are presented as mean + standard error of the mean (SEM).
Figure 5
Figure 5
PVT1 exons 7 (A) and 8 (B) expression in non-tumorigenic and tumorigenic prostate epithelial cell lines. Four independent qPCR experiments were performed and every experiment was set up in quadruplicates. The data showed that there is no significant differential expression of the exons in the cell lines in comparing cell lines derived from CM with those derived from MoAA. The data are presented as mean + standard error of the mean (SEM).
Figure 6
Figure 6
PVT1 exon 9 overexpression in aggressively tumorigenic PCa cell line from MoAA. Five independent qPCR experiments were performed and every experiment was set up in quadruplicates. The data showed that PVT1 exon 9 is consistently significantly overexpressed in the aggressive PCa cell lines derived from MoAA in comparison to the non-tumorigenic PCa cell line it was derived from. The data are presented as mean + standard error of the mean (SEM) and the p values are displayed on the figure. The lower panel shows the different prostate cell lines’ PVT1 exon 9 PCR products loaded on a 0.8% agarose gel.
Figure 7
Figure 7
PVT1 exon 9 expression in non-tumorigenic and tumorigenic prostate epithelial cell lines. At least three independent qPCR experiments were performed and every experiment was set up in quadruplicates. The data showed that PVT1 exon 9 is consistently significantly overexpressed in the aggressive PCA cell lines derived from MoAA. The data are presented as mean + standard error of the mean (SEM) and the p values are displayed on the figure, and are compared to the control (RWPE1 cell line).
See this image and copyright information in PMC

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 2015;65:5–29. doi: 10.3322/caac.21254. - DOI - PubMed
    1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013;63:11–30. doi: 10.3322/caac.21166. - VSports手机版 - DOI - PubMed
    1. Evans S., Metcalfe C., Ibrahim F., Persad R., Ben-Shlomo Y. Investigating Black-White differences in prostate cancer prognosis: A systematic review and meta-analysis. Int. J. Cancer. 2008;123:430–435. doi: 10.1002/ijc.23500. - DOI - PubMed
    1. Evans S., Metcalfe C., Patel B., Ibrahim F., Anson K., Chinegwundoh F., Corbishley C., Gillatt D., Kirby R., Muir G., et al. Clinical presentation and initial management of black men and white men with prostate cancer in the United Kingdom: The PROCESS cohort study. Br. J. Cancer. 2010;102:249–254. doi: 10.1038/sj.bjc.6605461. - V体育ios版 - DOI - PMC - PubMed
    1. Clegg L.X., Reichman M.E., Miller B.A., Hankey B.F., Singh G.K., Lin Y.D., Goodman M.T., Lynch C.F., Schwartz S.M., Chen V.W., et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: Selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control CCC. 2009;20:417–435. doi: 10.1007/s10552-008-9256-0. - DOI - PMC - PubMed

Publication types

Substances